HUP0302629A3 - Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer - Google Patents

Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer

Info

Publication number
HUP0302629A3
HUP0302629A3 HU0302629A HUP0302629A HUP0302629A3 HU P0302629 A3 HUP0302629 A3 HU P0302629A3 HU 0302629 A HU0302629 A HU 0302629A HU P0302629 A HUP0302629 A HU P0302629A HU P0302629 A3 HUP0302629 A3 HU P0302629A3
Authority
HU
Hungary
Prior art keywords
camptothecin
cancer
treatment
combination
pharmaceutical compositions
Prior art date
Application number
HU0302629A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of HUP0302629A2 publication Critical patent/HUP0302629A2/hu
Publication of HUP0302629A3 publication Critical patent/HUP0302629A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0302629A 2000-10-27 2001-10-25 Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer HUP0302629A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24343100P 2000-10-27 2000-10-27
US24558200P 2000-11-06 2000-11-06
US25013800P 2000-12-01 2000-12-01
PCT/EP2001/012985 WO2002034244A2 (en) 2000-10-27 2001-10-25 A combination comprising camptothecin and a stilbene derivative for the treatment of cancer

Publications (2)

Publication Number Publication Date
HUP0302629A2 HUP0302629A2 (hu) 2003-11-28
HUP0302629A3 true HUP0302629A3 (en) 2005-05-30

Family

ID=27399663

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302629A HUP0302629A3 (en) 2000-10-27 2001-10-25 Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer

Country Status (22)

Country Link
US (1) US6562834B2 (hu)
EP (1) EP1333820A2 (hu)
JP (1) JP2004517821A (hu)
KR (1) KR100742524B1 (hu)
CN (1) CN1200712C (hu)
AU (2) AU1602902A (hu)
BG (1) BG107806A (hu)
BR (1) BR0114856A (hu)
CA (1) CA2426898A1 (hu)
EA (1) EA005400B1 (hu)
EE (1) EE200300184A (hu)
HK (1) HK1058623A1 (hu)
HR (1) HRP20030382A2 (hu)
HU (1) HUP0302629A3 (hu)
IL (1) IL155509A0 (hu)
MX (1) MXPA03002882A (hu)
NO (1) NO324844B1 (hu)
NZ (1) NZ524855A (hu)
PL (1) PL365685A1 (hu)
SK (1) SK5122003A3 (hu)
WO (1) WO2002034244A2 (hu)
YU (1) YU29803A (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
TW200819409A (en) 2006-10-19 2008-05-01 Univ Taipei Medical Z-stilbenes derivatives and the pharmaceutical composition thereof
CA2826034A1 (en) 2011-01-28 2012-08-02 University Of Kentucky Research Foundation Stilbene analogs and methods of treating cancer
AU2012275841A1 (en) 2011-06-27 2014-01-16 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS57116015A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Antitumor agent
JPS57116074A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS595188A (ja) 1982-06-30 1984-01-12 Yakult Honsha Co Ltd 10−ヒドロキシカンプトテシンの製造法
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
CA1332413C (en) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
JP2524804B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体及びその製造法
JP2524803B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体およびその製造法
EP0540099B1 (en) 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5670500A (en) 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
PT835258E (pt) 1995-06-21 2003-02-28 Sod Conseils Rech Applic Novos analogos de camptotecina, processos para a sua preparacao, sua utilizacao como farmacos e composicoes farmaceuticas que os contem
JP3054669B2 (ja) 1995-10-16 2000-06-19 余川商事株式会社 積雪落下防止装置
JPH11296051A (ja) 1998-04-08 1999-10-29 Canon Inc プロセスカートリッジ
DE69942128D1 (de) * 1998-12-11 2010-04-22 Coulter Pharm Inc Prodrugs und verfahren zu deren herstellung
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
CA2432792C (en) 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis

Also Published As

Publication number Publication date
JP2004517821A (ja) 2004-06-17
KR20030082544A (ko) 2003-10-22
NO20031656L (no) 2003-04-10
BG107806A (bg) 2004-06-30
IL155509A0 (en) 2003-11-23
HUP0302629A2 (hu) 2003-11-28
AU2002216029B2 (en) 2006-01-05
US20020115677A1 (en) 2002-08-22
HK1058623A1 (en) 2004-05-28
US6562834B2 (en) 2003-05-13
PL365685A1 (en) 2005-01-10
CN1471396A (zh) 2004-01-28
NO20031656D0 (no) 2003-04-10
EA200300516A1 (ru) 2003-08-28
NO324844B1 (no) 2007-12-17
HRP20030382A2 (en) 2005-04-30
WO2002034244A2 (en) 2002-05-02
MXPA03002882A (es) 2004-12-03
SK5122003A3 (en) 2003-12-02
BR0114856A (pt) 2004-06-15
KR100742524B1 (ko) 2007-08-02
EE200300184A (et) 2003-08-15
NZ524855A (en) 2004-10-29
AU1602902A (en) 2002-05-06
EA005400B1 (ru) 2005-02-24
WO2002034244A3 (en) 2003-05-30
CA2426898A1 (en) 2002-05-02
CN1200712C (zh) 2005-05-11
YU29803A (sh) 2006-05-25
EP1333820A2 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
HUP0501089A2 (en) Therapeutic isoquinoline compounds and pharmaceutical compositions coutaining them
AU6147401A (en) Compositions and methods for the treatment of cancer
IL148630A0 (en) Compounds and pharmaceutical compositions for inhibiting cathepsin s
EP1328284A4 (en) NEW MEDICAL HERBAL COMPOSITION FOR TREATING LIVER DISEASES AND HIV
IL154012A0 (en) Hydrogel-driven drug dosage form
AU2002226069A1 (en) Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer
HUP0302499A3 (en) Pharmaceutical compositions of estrogen-cyclodextrin complexes and process for their preparation
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
HK1044476A1 (en) Medicinal compositions
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
HU0103078D0 (en) Pharmaceutical compositions and methods for treating cataracts
HUP0300848A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
HUP0201187A3 (en) Use of ecteinascidin743 for producing pharmaceutical compositions suitable for treating cancer
HUP0302130A3 (en) Combination pharmaceutical compositions and process for their preparation
EP1166786A4 (en) MEDICAL COMPOSITIONS
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0302629A3 (en) Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
IL153487A0 (en) Pharmaceutical compositions and methods for use
GB0009609D0 (en) Therapeutic compositions
IL153897A0 (en) Pharmaceutical compositions and methods for use
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
EP1259255A4 (en) PAI-2 CONJUGATES FOR THE TREATMENT AND VISUALIZATION OF CANCERS
GB0030857D0 (en) Therapeutic compositions
IL155055A0 (en) Triazole derivatives and pharmaceutical compositions comprising them
AU2001252235A1 (en) A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: PFIZER ENTERPRISES SARL, LU

Free format text: FORMER OWNER(S): AVENTIS PHARMA S.A., FR

FD9A Lapse of provisional protection due to non-payment of fees